Expertise in
8
conditions

Alberto Fabbri

Siena, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Siena, IT 

Overview

Alberto Fabbri practices practicing medicine in Siena, Italy.

Mr. Fabbri is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 104 peer reviewed articles and participating in 16 clinical trials.

Gender

Male

Locations

Siena, Italy
Other Locations
Rome, Italy
Florence, Italy
Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Radiation, Other
Study Phase: Not Applicable
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Enrollment Status: Completed
Publish Date: December 08, 2025
Intervention Type: Drug
Study Drug: Venetoclax
Study Phase: Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas
Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Other
An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)
An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Drug, Radiation
Study Drugs: Methotrexate, Rituximab, Cytarabine, Thiotepa, Liposomal Cytarabine, Etoposide, Ifosfamide, Carmustine
Study Phase: Phase 2
A Phase II, Open Label, Multicenter Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in Patients With Relapsed/Refractory CD38 Positive Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal Lymphomas of TFH Cell Origin
A Phase II, Open Label, Multicenter Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in Patients With Relapsed/Refractory CD38 Positive Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal Lymphomas of TFH Cell Origin
Enrollment Status: Terminated
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: Daratumumab
Study Phase: Phase 2
Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
Enrollment Status: Completed
Publish Date: January 30, 2025
Intervention Type: Drug, Radiation
Study Drugs: Rituximab, Methotrexate, Procarbazine, Lenalidomide, Temozolomide
Study Phase: Phase 2
A Combination of Lenalidomide and Rituximab as Front Line Therapy for the Treatment of Elderly Frail Patients Evaluated in CGA With Diffuse Large B-cells Non-Hodgkin Lymphoma. A Phase II Study of the Fondazione Italiana Linfomi (FIL)
A Combination of Lenalidomide and Rituximab as Front Line Therapy for the Treatment of Elderly Frail Patients Evaluated in CGA With Diffuse Large B-cells Non-Hodgkin Lymphoma. A Phase II Study of the Fondazione Italiana Linfomi (FIL)
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drugs: Rituximab, Dexamethasone, Lenalidomide
Study Phase: Phase 2
Carfilzomib (K) Plus Lenalidomide (R) and Dexamethasone (D) for BTK Inhibitors Relapsed-refractory or Intolerant Mantle Cell Lymphomas: a Phase II Study
Carfilzomib (K) Plus Lenalidomide (R) and Dexamethasone (D) for BTK Inhibitors Relapsed-refractory or Intolerant Mantle Cell Lymphomas: a Phase II Study
Enrollment Status: Unknown
Publish Date: September 15, 2022
Intervention Type: Drug
Study Drugs: Carfilzomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
View 9 Less Clinical Trials

104 Total Publications

Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.
Journal: Leukemia & lymphoma
Published: January 29, 2026

Frequently Asked Questions about Alberto Fabbri

Is Alberto Fabbri a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Alberto Fabbri is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alberto Fabbri participate in research or clinical trials?

Yes. Alberto Fabbri has published 104 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Alberto Fabbri's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fabbri's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile